{
  "id": "6023598a1cb411341a00009b",
  "type": "list",
  "question": "Which molecules are targeted by Trastuzumab Deruxtecan?",
  "ideal_answer": "Trastuzumab deruxtecan is a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33118153",
    "http://www.ncbi.nlm.nih.gov/pubmed/32005279",
    "http://www.ncbi.nlm.nih.gov/pubmed/31825192",
    "http://www.ncbi.nlm.nih.gov/pubmed/29037983",
    "http://www.ncbi.nlm.nih.gov/pubmed/32469182",
    "http://www.ncbi.nlm.nih.gov/pubmed/31843763",
    "http://www.ncbi.nlm.nih.gov/pubmed/32058843",
    "http://www.ncbi.nlm.nih.gov/pubmed/30351177",
    "http://www.ncbi.nlm.nih.gov/pubmed/32144719",
    "http://www.ncbi.nlm.nih.gov/pubmed/31087550",
    "http://www.ncbi.nlm.nih.gov/pubmed/32917537",
    "http://www.ncbi.nlm.nih.gov/pubmed/31574081",
    "http://www.ncbi.nlm.nih.gov/pubmed/31047803",
    "http://www.ncbi.nlm.nih.gov/pubmed/31047804",
    "http://www.ncbi.nlm.nih.gov/pubmed/29703841"
  ],
  "snippets": [
    {
      "text": "The antibody-drug conjugate trastuzumab deruxtecan might become a promising new treatment option for patients with metastatic HER2-positive breast cancer whose disease has progressed after multiple therapies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31843763",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31825192",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31825192",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31825192",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32005279",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a topoisomerase I inhibitor payload. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32058843",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trastuzumab deruxtecan (ENHERTU\u00ae), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in collaboration with AstraZeneca.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32144719",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32469182",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and topoisomerase I inhibitor payload.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31047804",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and potent topoisomerase I inhibitor payload.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31047803",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32469182",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[fam-] trastuzumab deruxtecan (DS-8201a) is a novel antibody-drug conjugate composed of the anti-HER2 antibody and the topoisomerase I inhibitor, an exatecan derivative.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31087550",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trastuzumab deruxtecan (also known as DS-8201) is an antibody-drug conjugate comprised of a humanised antibody against HER2, a novel enzyme-cleavable linker, and a topoisomerase I inhibitor payload.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29037983",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32469182",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[Fam-] trastuzumab deruxtecan (DS-8201a) is a HER2 (ERBB2)-targeting antibody-drug conjugate, composed of a HER2-targeting antibody and a topoisomerase I inhibitor, exatecan derivative, that has antitumor effects in preclinical xenograft models and clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31574081",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) conjugated to a topoisomerase I inhibitor (DXd) at a drug-to-antibody ratio (DAR) of 7-8.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30351177",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32469182",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trastuzumab deruxtecan (DS-8201) is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate with a novel enzyme-cleavable linker, a topoisomerase I inhibitor payload, and a drug-to-antibody ratio of \u2248 8.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33118153",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with a topoisomerase I inhibitor exatecan derivative (DX-8951 derivative, DXd), has been reported to exert potent antitumor effects in xenograft mouse models and clinical trials. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29703841",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trastuzumab deruxtecan (DS-8201a) is a next-generation antibody-drug conjugate composed of a monoclonal anti-HER2 antibody and a topoisomerase I inhibitor, an exatecan derivative (DX-8951f).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32917537",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "HER2, DNA topoisomerase I"
}